Drug intelligence / Profile preview

JW0108

Development stage: Unknown
Lead developer: JW Pharmaceutical

Overview

JW0108 is a drug under clinical investigation by JW Pharmaceutical and is being developed in combination with C2407 for the treatment of dyslipidemia. Its specific mechanism of action and molecular modality have not been publicly disclosed as of July 2025, but it is being evaluated for its efficacy and safety in lowering or managing abnormal blood lipid levels in patients with dyslipidemia. JW0108 is currently in a Phase 3 clinical trial as part of a fixed-dose combination therapy with C2407[1][2][3][9][10].

Other names: JW0108JW-0108JW 0108

Beyond the preview

Go deeper on JW0108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JW0108.

Explore the full profile